Home / News / Events / Events detail
On Aug 3, the 6th Viva Live Broadcast officially launched. Dr. Jason Jiang, Associate of Viva BioInnovator, shared his insights on "Development and Innovation of Targeted Radionuclide Drugs." He introduced the overview of radionuclide drugs and the newcomer "RDC drugs." He said that alongside the rise of ADC R&D and BD, RDC, which is also a drug conjugate, has formed a new track. Compared with the crowded ADC track, RDC provides a new research direction and continues to heat up in the market.
Dr. Jason Jiang also introduced the layout of VBI in the field of radionuclide drugs and its' empowerment and support to its portfolio companies. VBI will continue to focus on building professional post-investment management, improving its service capabilities from CRO/CDMO services, expert support, funding, industry network, and operations to help global biopharmaceutical companies innovate and grow.
Please watch the video record of the broadcast through Tencent Video or BiliBili.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us